Two plaintiffs afflicted with Parkinson’s disease have lost their attempt to compel a drug company to continue giving them an experimental treatment.
Southern District Judge P. Kevin Castel upheld the right of New York-based Amgen Inc. to terminate experimental trials for treatment of the neurodegenerative disease by refusing to grant a preliminary injunction sought by two patients who claimed the company overreacted to data showing the treatment risked worsening their conditions.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
